PE20070111A1 - Aminopirimidinas como moduladores de quinasas - Google Patents
Aminopirimidinas como moduladores de quinasasInfo
- Publication number
- PE20070111A1 PE20070111A1 PE2006000639A PE2006000639A PE20070111A1 PE 20070111 A1 PE20070111 A1 PE 20070111A1 PE 2006000639 A PE2006000639 A PE 2006000639A PE 2006000639 A PE2006000639 A PE 2006000639A PE 20070111 A1 PE20070111 A1 PE 20070111A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- piperazin
- heteroaryl
- amino
- tyrosine kinase
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 150000005005 aminopyrimidines Chemical class 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 PHENOXY, PHENYL Chemical class 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- MLNFMFAMNBGAQT-UHFFFAOYSA-N 4-propan-2-yloxyaniline Chemical compound CC(C)OC1=CC=C(N)C=C1 MLNFMFAMNBGAQT-UHFFFAOYSA-N 0.000 abstract 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract 1
- 101001052849 Homo sapiens Tyrosine-protein kinase Fer Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract 1
- 102100024537 Tyrosine-protein kinase Fer Human genes 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE r ES 1-2; Z ES NH, N(ALQUILO), CH2; B ES FENILO, HETEROARILO, HETEROARILO BENZOFUSIONADO DE 9-10 MIEMBROS; R1 ES -(CH2)nRa; n ES 1-4; Ra ES H, ALCOXI, FENOXI, FENILO, HETEROARILO, ENTRE OTROS; R3 ES H, ALQUILO, ALCOXI, HALOGENO, TIO, HALOGENO, NITRO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (4-ISOPROPOXI-FENIL)-AMIDA DEL ACIDO 4-[6-AMINO-5-(,ETOXIIMINO-METIL)-PIRIMIDIN-4-IL]-PIPERAZIN-1-CARBOXILICO; (4-PIPERIDIN-1-IL-FENIL)-AMIDA DEL ACIDO 4-{6-AMINO-5-[(2-MORFOLIN-4-IL-ETOXIIMINO)-METIL]-PIRIMIDIN-4-IL}-PIPERAZIN-1-CARBOXILICO; O-METIL-OXIMA DE 4-AMINO-6-{4-[2-(4-ISOPROPIL-FENIL)-ACETIL]-PIPERAZIN-1-IL}-PIRIMIDIN-5-CARBALDEHIDO; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE FLT3 (LIGANDO DE TIROSINA QUINASA 3), C-KIT (RECEPTOR DE TIROSINA QUINASA) Y/O TRKB (TIROSINA QUINASA TIPO B) UTILES EN EL TRATAMIENTO DE CANCER Y OTROS TRASTORNOS DE PROLIFERACION CELULAR
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68971505P | 2005-06-10 | 2005-06-10 | |
| US75108305P | 2005-12-16 | 2005-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20070111A1 true PE20070111A1 (es) | 2007-02-09 |
Family
ID=36930537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000639A PE20070111A1 (es) | 2005-06-10 | 2006-06-08 | Aminopirimidinas como moduladores de quinasas |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20070021435A1 (es) |
| EP (1) | EP1898917B1 (es) |
| JP (1) | JP2008545797A (es) |
| KR (1) | KR20080026592A (es) |
| AR (1) | AR054388A1 (es) |
| AT (1) | ATE420646T1 (es) |
| AU (1) | AU2006258039A1 (es) |
| BR (1) | BRPI0611597A2 (es) |
| CA (1) | CA2611495A1 (es) |
| CR (1) | CR9649A (es) |
| DE (1) | DE602006004873D1 (es) |
| EA (1) | EA200800018A1 (es) |
| EC (1) | ECSP077994A (es) |
| ES (1) | ES2319574T3 (es) |
| GT (1) | GT200600253A (es) |
| IL (1) | IL187686A0 (es) |
| MX (1) | MX2007015742A (es) |
| NI (1) | NI200700313A (es) |
| NO (1) | NO20080161L (es) |
| PE (1) | PE20070111A1 (es) |
| TW (1) | TW200716118A (es) |
| UY (1) | UY29591A1 (es) |
| WO (1) | WO2006135719A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060281755A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators |
| KR20080043840A (ko) * | 2005-09-13 | 2008-05-19 | 팔라우 파르마 에스에이 | 히스타민 ｈ4 수용체 활성의 조정자로서 2-아미노피리미딘유도체 |
| CA2677108A1 (en) | 2007-03-02 | 2008-09-12 | Genentech, Inc. | Predicting response to a her inhibitor |
| WO2013113781A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds i |
| EA201491472A1 (ru) | 2012-02-03 | 2015-01-30 | Басф Се | Фунгицидные соединения пиримидина |
| WO2013113787A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113776A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| IN2014DN07224A (es) | 2012-02-03 | 2015-04-24 | Basf Se | |
| WO2013113773A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113782A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113716A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113719A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds ii |
| WO2013135672A1 (en) | 2012-03-13 | 2013-09-19 | Basf Se | Fungicidal pyrimidine compounds |
| IN2014DN07954A (es) | 2012-03-13 | 2015-05-01 | Basf Se | |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1206265B1 (en) * | 1999-06-30 | 2003-11-12 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| WO2003026666A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors |
-
2006
- 2006-06-06 US US11/422,366 patent/US20070021435A1/en not_active Abandoned
- 2006-06-07 JP JP2008515951A patent/JP2008545797A/ja not_active Withdrawn
- 2006-06-07 AT AT06772650T patent/ATE420646T1/de not_active IP Right Cessation
- 2006-06-07 ES ES06772650T patent/ES2319574T3/es active Active
- 2006-06-07 NI NI200700313A patent/NI200700313A/es unknown
- 2006-06-07 BR BRPI0611597-7A patent/BRPI0611597A2/pt not_active IP Right Cessation
- 2006-06-07 CA CA002611495A patent/CA2611495A1/en not_active Abandoned
- 2006-06-07 KR KR1020087000220A patent/KR20080026592A/ko not_active Withdrawn
- 2006-06-07 EA EA200800018A patent/EA200800018A1/ru unknown
- 2006-06-07 MX MX2007015742A patent/MX2007015742A/es unknown
- 2006-06-07 EP EP06772650A patent/EP1898917B1/en active Active
- 2006-06-07 AU AU2006258039A patent/AU2006258039A1/en not_active Abandoned
- 2006-06-07 DE DE602006004873T patent/DE602006004873D1/de not_active Expired - Fee Related
- 2006-06-07 WO PCT/US2006/022411 patent/WO2006135719A1/en not_active Ceased
- 2006-06-08 PE PE2006000639A patent/PE20070111A1/es not_active Application Discontinuation
- 2006-06-08 UY UY29591A patent/UY29591A1/es unknown
- 2006-06-08 GT GT200600253A patent/GT200600253A/es unknown
- 2006-06-09 AR ARP060102427A patent/AR054388A1/es not_active Application Discontinuation
- 2006-06-09 TW TW095120480A patent/TW200716118A/zh unknown
-
2007
- 2007-11-27 IL IL187686A patent/IL187686A0/en unknown
- 2007-12-10 EC EC2007007994A patent/ECSP077994A/es unknown
-
2008
- 2008-01-09 CR CR9649A patent/CR9649A/es not_active Application Discontinuation
- 2008-01-09 NO NO20080161A patent/NO20080161L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006135719A1 (en) | 2006-12-21 |
| UY29591A1 (es) | 2006-10-02 |
| HK1116059A1 (en) | 2008-12-19 |
| ES2319574T3 (es) | 2009-05-08 |
| ECSP077994A (es) | 2008-01-23 |
| BRPI0611597A2 (pt) | 2010-09-21 |
| GT200600253A (es) | 2007-01-12 |
| AR054388A1 (es) | 2007-06-20 |
| MX2007015742A (es) | 2008-04-29 |
| EP1898917B1 (en) | 2009-01-14 |
| CR9649A (es) | 2008-09-09 |
| US20070021435A1 (en) | 2007-01-25 |
| JP2008545797A (ja) | 2008-12-18 |
| EP1898917A1 (en) | 2008-03-19 |
| TW200716118A (en) | 2007-05-01 |
| CA2611495A1 (en) | 2006-12-21 |
| ATE420646T1 (de) | 2009-01-15 |
| NI200700313A (es) | 2009-03-24 |
| DE602006004873D1 (de) | 2009-03-05 |
| IL187686A0 (en) | 2008-08-07 |
| KR20080026592A (ko) | 2008-03-25 |
| NO20080161L (no) | 2008-01-28 |
| EA200800018A1 (ru) | 2008-06-30 |
| AU2006258039A1 (en) | 2006-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20070111A1 (es) | Aminopirimidinas como moduladores de quinasas | |
| PE20091243A1 (es) | Compuesto heterociclico fusionado | |
| PE20130382A1 (es) | Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a | |
| PE20080345A1 (es) | Derivados de piperazina como agonistas del receptor de gpr38 | |
| RU2006107785A (ru) | 2, 4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств | |
| PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| PE20091955A1 (es) | Derivados de quinoxalin- y quinolin-carboxamida | |
| PE20070113A1 (es) | Derivados de quinolina y quinazolina como inhibidores de tirosinquinasas flt3 y trkb | |
| PE20100138A1 (es) | Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k | |
| PE20090992A1 (es) | Derivados de fenil-amino-pirimidina como agentes inhibidores de cinasa | |
| PE20091466A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il-amina | |
| PE20090982A1 (es) | Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp) | |
| PE20100087A1 (es) | Compuestos y composiciones como inhibidores de cinasa | |
| PE20080944A1 (es) | Derivados de pirimidina como inhibidores del receptor de cinasa activina(alk-5) | |
| PE20080404A1 (es) | Derivados bencil-amino-piperidina como inhibidores de cetp | |
| PE20061442A1 (es) | Heterociclicos como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia | |
| TR200701870T1 (tr) | İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem. | |
| PE20081359A1 (es) | Compuestos de azabenzotiofenil como inhibidores de la quinasa mek | |
| PE20081059A1 (es) | Derivados de pirimidinas como inhibidores de la actividad de la tirosina quinasa de bruton (btk) | |
| PE20070790A1 (es) | Derivados de 2-aminopirimidina como moduladores de la actividad del receptor de histamina h-4 | |
| PE20130235A1 (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
| PE20060589A1 (es) | FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b | |
| PE20091204A1 (es) | Derivados de 2-aminoquinolina como antagonistas del receptor de 5-ht5a | |
| PE20071156A1 (es) | COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA) | |
| PE20080094A1 (es) | COMPUESTOS DE DIALQUILFENILO CON ACTIVIDAD AGONISTA DEL RECEPTOR ß2 ADRENERGICO Y ANTAGONISTA DEL RECEPTOR MUSCARINICO |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |